174180-76-8

Basic information

• Product Name: TERT-BUTYL 3-(BROMOMETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 3-(BROMOMETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLATE;1H-Pyrazolo[3,4-b]pyridine-1-carboxylic acid, 3-(broMoMethyl)-,1,1-diMethylethyl ester;3-broMoMethylpyrazolo[3,4-b]pyridine-1-carboxylic acid tert-butyl este;3-broMoMethylpyrazolo[3,4-b]pyridine-1-carboxylic acid tert-butyl ester;3-(Bromomethyl)-1H-pyrazolo[3,4-b]pyridine-1-carboxylic acid tert-butyl ester;1-Boc-3-bromomethyl-1H-pyrazolo[3,4-b]pyridine
• CAS NO: 174180-76-8
• Molecular Formula: C₁₂H₁₄BrN₃O₂
• Molecular Weight: 312.17
• Mol File: 174180-76-8.mol

Chemical Properties

• Melting Point: 85-86℃
• Boiling Point: 409.639°C at 760 mmHg
• Flash Point: 201.542°C
• Appearance: /
• Density: 1.5g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: TERT-BUTYL 3-(BROMOMETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3-(BROMOMETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLATE(174180-76-8)
• EPA Substance Registry System: TERT-BUTYL 3-(BROMOMETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLATE(174180-76-8)

Safety Data

• Hazardous Substances Data: 174180-76-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
TERT-BUTYL 3-(BROMOMETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLATE is used as a reagent for the introduction of pyrazole-containing moieties in organic synthesis, providing a foundation for the creation of various organic compounds with potential applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, TERT-BUTYL 3-(BROMOMETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLATE is utilized as a key intermediate for the development of new pharmaceuticals, leveraging its ability to modulate biological targets and contribute to drug discovery.
Used in Drug Discovery and Development:
TERT-BUTYL 3-(BROMOMETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLATE is employed as a versatile building block in drug discovery and development, enabling the synthesis of compounds with potential pharmacological activities, which can be further optimized for therapeutic applications.
Used in Pharmaceutical Industry:
Within the pharmaceutical industry, TERT-BUTYL 3-(BROMOMETHYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-1-CARBOXYLATE is used as a component in the synthesis of novel drug candidates, capitalizing on its structural features to enhance the properties and effectiveness of new medications.

InChI:InChI=1/C12H14BrN3O2/c1-12(2,3)18-11(17)16-10-8(5-4-6-14-10)9(7-13)15-16/h4-6H,7H2,1-3H3

Upstream product

• 174180-77-9 tert-butyl 3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 
• 79574-70-2 1-(2-fluoropyridin-3-yl)ethan-1-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 116834-96-9 3-methyl-1H-pyrazolo[3,4b]pyridine 
• 372-48-5 2-fluoropyridine 
• 55676-21-6 3-acetyl-2-chloropyridine 
• 2942-59-8 2-chloronicotinic acid 

Downstream Products

• 1071568-88-1 tert-butyl 3-[4-chloro-2-(3-chloro-5-cyano-benzoyl)-phenoxymethyl]-pyrazolo[3,4-b]pyridine-1-carboxylate 
• 1071569-17-9 C₂₅H₂₀Cl₂N₄O₄ 
• 1071568-91-6 C₂₅H₂₂ClN₃O₄ 
• 1071568-83-6 C₂₅H₁₉ClFN₅O₆ 
• 1072250-03-3 tert-butyl 3-{[4-chloro-3-(3-chloro-5-cyanophenoxy)phenoxy]methyl}-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 
• 1173989-68-8 C₂₇H₁₇Cl₂N₇O₂ 
• 1155847-27-0 2-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetic acid 
• 1155846-90-4 3-(aminomethyl)-1H-pyrazolo[3,4-b]pyridine 
• 1034474-19-5 3-chloro-5-{[5-chloro-1-(1H-pyrazolo[3,4-b]pyridin-3-ylmethyl)-1H-indazol-4-yl]oxy}benzonitrile 
• 1034474-22-0 2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-1H-1,2,3-benzotriazol-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridin-1-yl)carbonyl](methyl)amino]-N-methylethanaminium chloride 
• 1034474-24-2 2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-1H-1,2,3-benzotriazol-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridin-1-yl)carbonyl](methyl)amino]ethanaminium chloride 
• 1034474-45-7 tert-butyl {2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-1H-1,2,3-benzotriazol-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridin-1-yl)carbonyl](methyl)amino]ethyl}methylcarbamate 
• 1034474-46-8 tert-butyl {2-[[(3-{[5-chloro-4-(3-chloro-5-cyanophenoxy)-1H-1,2,3-benzotriazol-1-yl]methyl}-1H-pyrazolo[3,4-b]pyridin-1-yl)carbonyl](methyl)amino]ethyl}carbamate 
• 1034474-21-9 3-chloro-5-{[5-chloro-1-(1H-pyrazolo[3,4-b]pyridin-3-ylmethyl)-1H-1,2,3-benzotriazol-4-yl]oxy}benzonitrile 

Relevant articles and documents

PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS

Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): Formula (I) wherein R', R2, L', and L2 are as defined herein.

NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS

The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.

Discovery of (S)-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure-activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.

NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS

The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.

Discovery of phenylaminopyridine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors

We identified a novel class of aryl-substituted triazine compounds as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) during a high-throughput screening campaign that evaluated more than 200000 compounds for antihuman immunodeficiency virus (HIV) activity using a cell-based full replication assay. Herein, we disclose the optimization of the antiviral activity in a cell-based assay system leading to the discovery of compound 27, which possessed excellent potency against wild-type HIV-1 (EC50 = 0.2 nM) as well as viruses bearing Y181C and K103N resistance mutations in the reverse transcriptase gene. The X-ray crystal structure of compound 27 complexed with wild-type reverse transcriptase confirmed the mode of action of this novel class of NNRTIs. Introduction of a chloro functional group in the pyrazole moiety dramatically improved hERG and CYP inhibition profiles, yielding highly promising leads for further development.

Development of practical syntheses of potent non-nucleoside reverse transcriptase inhibitors

The development of practical and efficient syntheses of the potent non-nucleoside reverse transcriptase inhibitors 1 and 2 is described. The preparation of 1 proceeded in four synthetic steps and in 48% overall yield from 3. The long-term synthesis of 2 proceeded in nine synthetic steps and in 47% overall yield from commercially available 2,6-diflurorpyridine. The route to 2 was highlighted by the three-step synthesis of intermediate 22 and the high yielding coupling between 18 and phenol 8. The overall sequence required no chromatography and has successfully been utilized for the manufacture of 2 on large scale.

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Compounds of Formula I: (I), are HIV reverse transcriptase inhibitors, wherein Q, R2, R3, R6, T1, T2, and T3 are defined herein. The compounds of Formula I, and the pharmaceutically accepta

HIV reverse transcriptase inhibitors

Compounds having the structure: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

CCK or gastrin modulating benzo ?b!?1,4! diazepines derivatives

Benzo?b!?1,4!diazepine compounds of formula (I), where R1 is selected from C1 C6 alkyl, C3 -C6 cycloalkyl, phenyl, or substituted phenyl; R2 is selected from C3 -C6 alkyl, C3 C6 cycloalkyl, C3 -C6 alkenyl, benzyl, phenylC1 -C3 alkyl of substituted phenyl; or NR1 R2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C1-6 alkyl C1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R3, R5, and R6 are independently hydrogen or C1-6 alkyl; R4 is C1-6 alkyl or C1-6 alkenyl; R7 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 cycloalkyl, C1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR6 R7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R8 and R9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).

Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists

We previously described a series of 3-(1H-indazol-3-ylmethyl)-1,5- benzodiazepine CCK-A agonists exemplified by compound 1 (GW 5823), which is the first reported binding selective CCK-A full agonist demonstrating oral efficacy in a rat feeding model. In this report we describe analogs of compound 1 designed to explore changes to the CS and N1 pharmacophores and their effect on agonist activity and receptor selectivity. Agonist efficacy in this series was affected by stereoelectronic factors within the C3 moiety. Binding affinity for the CCK-A vs CCK-B receptor showed little dependence on the structure of the C3 moiety but was affected by the nature of the second substituent at CS. Structure-activity relationships at the N1- anilidoacetamide 'trigger' moiety within the C3 indazole series were also investigated. Both agonist efficacy and binding affinity within this series were modulated by variation of substituents on the Nl-anilidoacetamide moiety. Evaluation of several analogs in an in vivo mouse gallbladder emptying assay revealed compound 1 to be the most potent and efficacious of all the analogs tested. The pharmacokinetic and pharmacodynamic profile of 1 in rats is also discussed.